Antineoplastic Detoxifying Agents Market
Number of pages: 100 | Report Format: PDF | Published date: May 11, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
8.1% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug, Cancer Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global antineoplastic detoxifying agents market is expected to register a revenue CAGR of 8.1% in forecast period from 2023 to 2031.
Antineoplastic Detoxifying Agents Market Fundamentals
The term antineoplastic toxicity is used to describe the unfavorable consequences that can come from chemotherapy, radiation therapy, immunotherapy, or other targeted therapies used to treat cancer. A crucial component of cancer treatment is managing these toxicities, which may entail supportive care techniques including medicine, dietary therapy, or other interventions to lessen their negative effects on patients' health and wellbeing. Antineoplastic detoxification agents are used to reduce or avoid the toxic side effects of chemotherapy medications used to treat cancer.
The development of antineoplastic detoxification agents has recently made a number of strides that are intended to increase the safety and effectiveness of chemotherapy treatment. One instance is the creation of pegfilgrastim, a long-acting version of the medication filgrastim used to lower the risk of infection in chemotherapy patients. Nano formulations of chemotherapy medications have also been created as a result of advancements in nanotechnology, which can increase drug delivery to cancer cells while lowering toxicity to healthy cells. For instance, liposomal doxorubicin formulations have demonstrated a reduction in the occurrence of cardiotoxicity, a significant adverse effect of this medication.
The global antineoplastic detoxifying agents industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the antineoplastic detoxifying agents market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the Antineoplastic detoxifying agents market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other vital information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Antineoplastic Detoxifying Agents Market Dynamics
The rising incidence of cancer globally and the expanding use of chemotherapy as a treatment option are two factors influencing the global antineoplastic detoxification agents market dynamics. According to the International Agency for Research on Cancer, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and about 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) were recorded in 2020. With an expected 2.3 million new cases (11.7%) in coming years. Also, female breast cancer has surpassed lung cancer as the most commonly diagnosed malignancy, followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancers. There is an increasing need for efficient and secure chemotherapy medications that can reduce the danger of toxicity and side effects as cancer incidence keeps rising. To increase the safety and effectiveness of chemotherapy, this has prompted a surge in research and development in the area of antineoplastic detoxifying agents. For instance, a recent study performed on 77 cancer patients receiving neoadjuvant treatment showed that 97.4% of patients suffered at least one side event throughout the six-month follow-up period. The most prevalent side effect was fatigue (87%), followed by lack of appetite (71.4%) and diarrhea (49.4%). Six or more side events were reported by around 66.7% of participants. The market for antineoplastic detoxification agents is also driven by the rising need for customized medicine and targeted therapies since these agents can be used to protect healthy cells while administering chemotherapy to malignant cells.
However, one of the key hurdles in the antineoplastic detoxification agents market is the high cost of developing and manufacturing these agents. Furthermore, regulatory approval can be a time-consuming and complex process, impeding the growth and commercialization of antineoplastic detoxification agents.
Antineoplastic Detoxifying Agents Market Ecosystem
This report provides the global antineoplastic detoxifying agents market analysis in terms of revenue, market growth, market dynamics, regional landscape and overall competitive positioning of the major market players. The global antineoplastic detoxifying agents market overview is analyzed from the following perspectives,
Antineoplastic Detoxifying Agents Market, by Drug Type
Antineoplastic detoxifying agents Market, by Cancer Type
Antineoplastic Detoxifying Agents Market by Drug Type
[111]
Based on the drug types, the global antineoplastic detoxifying agents market is segmented into palifermin, dexrazoxane, leucovorin, amifostine, levoleucovorin, and others.
Dexrazoxane segment accounted for the global market's largest revenue share in terms of the antineoplastic detoxifying agents market forecast. Dexrazoxane is a well-established and widely used antineoplastic detoxifying agent for reducing cardiotoxicity caused by anthracycline chemotherapy. Its effectiveness in reducing the incidence and severity of cardiotoxicity and its favorable safety profile have contributed to its dominance in the market share of antineoplastic detoxifying agents. Dexrazoxane is administered to prevent or reduce the incidence of cardiotoxicity caused by anthracycline chemotherapy drugs. Cardiotoxicity is a potential side effect of chemotherapy, which can cause damage to the heart muscle and lead to heart failure. Certain chemotherapy medicines, such as anthracyclines and HER2-targeted treatments, increase the risk of cardiotoxicity. According to the University of Rochester Medical Center, between 5% to 15% of cancer patients develop full-blown heart failure after surviving cancer. Also, according to NIH, depending on the kind of heart problem, the incidence of cardiotoxicity in adult patients can reach 50%.
The market segmentation sections provide the antineoplastic detoxifying agents market outlook in terms of the demarcation of different consumer groups. Market segmentation is splitting an industry into subgroups depending on characteristics such as drug type, cancer type, and other factors. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential antineoplastic detoxifying agents market demand opportunities.
Antineoplastic Detoxifying Agents Market By Region
Geographically, the lobal gantineoplastic detoxifying agents market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.
According to the antineoplastic detoxifying agents industry analysis, North America accounted for the largest revenue share of the global market in 2022. The region has a high prevalence of cancer, which has led to a greater demand for chemotherapy drugs and subsequently, for chemoprotective agents. In 2022, United States accounts for almost 60% of the market share in North America. According to CDC, in the United States, 1,752,735 new cancer cases were reported in 2019, while 599,589 people died from the disease. 439 new cases of cancer and 146 cancer-related deaths were reported for every 100,000 persons. Furthermore, the presence of key market players in North America, along with the growing adoption of newer and more effective chemoprotective agents, has further contributed to the dominance of the region in the antineoplastic detoxifying agents market.
Based on the regions, the global antineoplastic detoxifying agents market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of antineoplastic detoxifying agents industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level antineoplastic detoxifying agents market overview.
Key Components of the Report
Antineoplastic Detoxifying Agents Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
• Antineoplastic detoxifying agents manufacturers, distributors, developers, and regulators of products
• New entrants into the market, start-ups, investors, and equity firms
• Government organizations and associations
• Industry organizations, associations, advocacy groups, forums, and reporting agencies
Antineoplastic detoxifying agents are used to counteract or prevent the toxic effects of antineoplastic chemotherapy drugs.
North America has the largest antineoplastic detoxifying agents market size during the forecast period from 2023 to 2031.
The global antineoplastic detoxifying agents market is expected to grow at a revenue CAGR of 8.1% during the forecast period from 2023 to 2031.
Lack of knowledge about antineoplastic detoxifying agents and stringent regulatory approvals are the major challenges hampering the growth of the global antineoplastic detoxifying agents market.
The major strategies key market players adopt involve strategic partnerships and collaborations to expand their market reach and capabilities.
Increased research and development to invent new antineoplastic detoxifying agents and raised awareness for safer cancer treatments are the most important drivers of the global market.
Key players in the global antineoplastic detoxifying agents market are Amgen Inc., Pfizer Inc., VHB Lifesciences Inc., Sun Pharmaceutical Industries Limited, Miracalus Pharma Pvt Ltd.
Dexrazoxane has the highest share in the global antineoplastic detoxifying agents market.
Increasing cancer prevalence necessitates introduction of new chemoprotective drugs are the major opportunities in the antineoplastic detoxifying agents market.
*Insights on financial performance are subject to the availability of information in the public domain